EGF Theramed Health (TMED) AI Stock Analysis

• Market Cap: C$929.33K
• Dividend Yield: N/A
• Average Volume (3M): 1.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.12
• Revenue Growth: N/A
• EPS Growth: -1188.37%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): >-0.01
• Shares Outstanding: 11,616,665
• 10 Day Avg. Volume: 1,800
• 30 Day Avg. Volume: 1,233
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.26
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 38.98
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: C$0.08 ▲(7.14% Upside)
• Action: Reiterated Date: 12/30/25
• Date: Action: Reiterated 12/30/25

The score is driven down primarily by very weak financial performance (no revenue, ongoing losses, negative equity and a thin asset base), compounded by strongly bearish technical momentum (below key moving averages with negative MACD and extremely low RSI). Valuation offers limited support because earnings are negative and no dividend yield is available.

Positive Factors

Recent cash flow improvement

A shift to slightly positive operating and free cash flow in 2025 demonstrates early operational stabilization and reduced near-term cash burn. If maintained, even small positive cash generation lowers immediate financing needs and provides a foundation for gradual reinvestment or restructuring over the next several months.

Improving loss trajectory

A materially smaller loss trend versus the 2020 trough indicates management has cut costs or narrowed operational exposures. Sustained loss reduction improves runway and flexibility, making a path to break-even more plausible if revenue initiatives or further efficiency measures are executed over the medium term.

Industry structural demand

Exposure to healthcare information services aligns the company with secular trends: digitalization of medical records, analytics and compliance needs. These structural tailwinds create a durable addressable market that can support sustainable revenue opportunities if the company establishes viable products and commercial execution.

Negative Factors

No reported revenue

Zero reported revenue means the business lacks measurable commercial traction or recurring customers, making long-term viability dependent on securing financing or rapid product-market fit. Without revenue, scalable economics and margin sustainability remain unproven and risky over the next several months.

Negative equity and tiny asset base

Negative equity with a minimal asset base and meaningful debt signals elevated solvency and recapitalization risk. Limited financial flexibility increases the likelihood of dilution, restructuring or creditor action, constraining the company's ability to invest or execute a turnaround over the medium term.

Persistent operating losses and volatile cash

Ongoing EBIT/EBITDA losses combined with volatile free cash flow mean the business still consumes capital and can’t reliably self-fund growth. This pattern raises refinancing risk and hinders consistent investment in product development or sales capacity, limiting durable improvement prospects.

EGF Theramed Health Business Overview & Revenue Model

Company Description

EGF Theramed Health Corp. provides psychedelic drugs for the treatment of mental health. It offers psychedelics for the treatment of conditions, such as treatment-resistant depression, anxiety, PTSD, and depression. The company was incorporated in 2011 and is headquartered in Vancouver, Canada.

How the Company Makes Money

null

EGF Theramed Health Financial Statement Overview

Summary

Financial quality is very weak: revenue is reported at $0 across all years, losses persist and worsened in 2025, and operating results (EBIT/EBITDA) remain negative. The balance sheet is highly stressed with negative equity (2022–2025), a very small asset base, and meaningful debt—indicating elevated solvency and dilution risk. Cash flow improved with slightly positive operating/free cash flow in 2025, but the magnitude is small and volatility remains high.

Income Statement

Financial performance is very weak: revenue is reported at $0 across all years provided, while losses persist every year. Net losses improved materially from the very large 2020 loss (about -$20.4M) to smaller losses in 2021–2024, but then deteriorated again in 2025 (about -$3.2M). Operating results remain firmly negative (EBIT and EBITDA losses), indicating the business has not reached a sustainable earnings base.

Balance Sheet

The balance sheet is highly stressed. Stockholders’ equity is negative from 2022–2025 (around -$4.5M in 2025), which is a major solvency red flag and implies liabilities exceed assets. Debt remains meaningful (about $1.5M in 2025) while the asset base is very small (about $22K in 2025), suggesting limited financial flexibility and elevated recapitalization/dilution risk.

Cash Flow

Cash flow is mixed but shows a near-term improvement. Operating and free cash flow were negative from 2020–2024, but turned slightly positive in 2025 (about +$30K). That said, the recent cash generation appears small relative to the scale of reported losses, and free cash flow growth is volatile (including a sharp negative growth figure in 2025), highlighting uneven cash sustainability.

Breakdown	TTM	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	―
EBITDA	-2.21M	-2.33M	-238.64K	-568.50K	-1.35M	-677.89K
Net Income	-3.09M	-3.21M	-269.25K	-623.00K	-1.69M	-968.71K
Balance Sheet
Total Assets	18.25K	22.34K	214.41K	193.69K	178.67K	1.20M
Cash, Cash Equivalents and Short-Term Investments	10.47K	14.01K	10.01K	11.72K	15.23K	702.63K
Total Debt	1.63M	1.51M	1.47M	1.34M	1.22M	1.12M
Total Liabilities	6.06M	5.93M	2.92M	2.67M	2.51M	2.41M
Stockholders Equity	-4.64M	-4.52M	-1.34M	-1.14M	-1.02M	91.48K
Cash Flow
Free Cash Flow	82.28K	29.75K	-134.71K	-576.01K	-993.42K	-783.76K
Operating Cash Flow	82.30K	29.75K	-134.71K	-576.01K	-993.42K	-783.76K
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	410.43K
Financing Cash Flow	104.98K	-25.75K	133.00K	572.50K	306.02K	712.20K

EGF Theramed Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.07
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TMED, the sentiment is Positive. The current price of 0.07 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.06, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 97.22 is Negative, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:TMED.

EGF Theramed Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NDAT	46 Neutral	C$4.34M	-4.56	-34.06%	―	-100.00%	65.85%
NARA	42 Neutral	C$6.25M	-4.68	―	―	―	81.01%
TMED	38 Underperform	C$929.33K	-2.71	78.43%	―	―	-1188.37%
KETA	38 Underperform	C$499.36K	-7.33	0.59%	―	―	―
DMED	33 Underperform	C$14.28M	-21.40	527.45%	―	―	-67.11%

EGF Theramed Health Corporate Events

EGF Theramed refreshes board and finance leadership

EGF Theramed Health Corp. has appointed Lin Ye to its board of directors and named Connor Yuen as interim chief financial officer, following the resignation of former CFO and director Usama Chaudhry. The changes bring leadership with experience in gaming, wagering, interactive technology and property management, which may support EGF’s operational execution and strategic planning as it develops its biomedical online services and medical technology assets.

The company highlighted Ye’s background in operational leadership, strategic planning, market expansion and asset optimization as an asset to its cross-sector growth ambitions. By refreshing its finance and board leadership, EGF appears to be positioning itself to strengthen governance and execution as it works to expand collaborations around its botanical extraction technologies and medical monitoring device platforms.

The most recent analyst rating on (TSE:TMED) stock is a Sell with a C$0.06 price target. To see the full list of analyst forecasts on EGF Theramed Health stock, see the TSE:TMED Stock Forecast page.